Last reviewed · How we verify
Quillivant XR
Quillivant XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.
Quillivant XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
At a glance
| Generic name | Quillivant XR |
|---|---|
| Also known as | methylphenidate hydrochloride oral suspension |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Drug class | Central nervous system stimulant; methylphenidate |
| Target | Dopamine transporter (DAT); norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate is a central nervous system stimulant that works by blocking the reuptake of dopamine and norepinephrine at the presynaptic neuron, increasing their availability in the synaptic cleft. The extended-release formulation provides sustained drug delivery throughout the day, allowing for once-daily dosing in patients with ADHD. This sustained elevation of catecholamines enhances focus, attention, and impulse control while reducing hyperactive and impulsive behaviors.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
Common side effects
- Decreased appetite
- Insomnia
- Headache
- Abdominal pain
- Nervousness
- Tachycardia
- Increased blood pressure
Key clinical trials
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (PHASE1)
- Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer (PHASE2)
- Treating Young Children With Attention Deficit Hyperactivity Disorder (PHASE4)
- AWARE: Management of ADHD in Autism Spectrum Disorder (PHASE4)
- Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits (PHASE4)
- Stimulant Effects on Disruptive Behavior (PHASE4)
- Evaluating Treatment of ADHD in Children with Down Syndrome (PHASE4)
- Biomarkers of ADHD Treatment Response (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quillivant XR CI brief — competitive landscape report
- Quillivant XR updates RSS · CI watch RSS
- Children's Hospital Medical Center, Cincinnati portfolio CI